WO1986000526A1 - Process for adapting soluble bone protein for use in stimulating osteoinduction - Google Patents

Process for adapting soluble bone protein for use in stimulating osteoinduction Download PDF

Info

Publication number
WO1986000526A1
WO1986000526A1 PCT/US1985/001291 US8501291W WO8600526A1 WO 1986000526 A1 WO1986000526 A1 WO 1986000526A1 US 8501291 W US8501291 W US 8501291W WO 8600526 A1 WO8600526 A1 WO 8600526A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
bone
releasing
dependent manner
time dependent
Prior art date
Application number
PCT/US1985/001291
Other languages
French (fr)
Inventor
Arnold I. Caplan
Glenn T. Syftestad
Original Assignee
Caplan Arnold I
Syftestad Glenn T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caplan Arnold I, Syftestad Glenn T filed Critical Caplan Arnold I
Publication of WO1986000526A1 publication Critical patent/WO1986000526A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/92Method or apparatus for preparing or treating prosthetic
    • Y10S623/923Bone

Definitions

  • This invention relates generally to a method for stimulating osteoinduction and more specifically to a process for adapting soluble 'regenerating' factors to effectively initiate new cartilage and/or bone growth at selected skeletal locations in humans and animals.
  • Regeneration of skeletal tissues is regulated by specific protein factors that are naturally present within bone matrix. During the healing process, these components stimulate certain cell populations to form new cartilage and bone tissue which serve to replace that which was lost or damaged.
  • protein substances if extracted and purified, have potential use in clinical situations where skeletal tissue regeneration is necessary to restore normal function, for example, at fracture sites and at sites of periodontal defects.
  • a protein substance can enhance or promote bony ingrowth into various prosthetic devices and bony implants, such as allografts, processed xenogenil bone chips and the like.
  • Bone matrix protein is readily soluble in body fluids. Its solubility precludes direct in_ vivo implantation at the site of a skeletal defect. For example, if a dissolvable capsule containing soluble bone protein is implanted at an ectopic intra-muscular site, no cartilage or bone induction occurs. Similarly no cartilage or bone, induction occurs when soluble bone protein is incorporated, by lyophilization, into an inert carrier (i.e., derrtineralized guanidinium chloride extracted cancellous or cortical bone chips) and implanted at ectopic sites. Diffusion of such soluble proteins away from the implant site occurs before the 1-2 days necessary for appropriate cell populations to accumulate. Thus, special procedures are required to 'immobilize' this substance in such a way that factor release coincides with the presence of sufficient numbers of responsive cell types which then will be stimulated to form cartilage and bone. Disclosure of the Invention
  • the invention provides a method of adapting soluble bone protein for use in osteoinduction and involves combining soluble bone protein purified to a state effective to initiate chondrogenesis with carrier means for retarding diffusion of said protein from a site of in vivo implantation.
  • the carrier means for retarding diffusion of soluble bone protein comprises a biocompatible, biodegradable mass capable of releasing the protein in a time dependent manner.
  • a preferred carrier of this class is a fibrin clot.
  • a fibrin clot is useful in that it can be molded to fit the contours of small defects such as periodontal pockets.
  • the carrier means comprises bony implant means such as allografts, specially processed xenogenic bone chips and the like, treated so as to be capable of releasing the protein in a time dependent manner.
  • the bony implant means can be treated by soaking in a surface coating solution, such as a gelatin or fibrin solution or the like, that is capable of being dried to form an adherent, biodegradable coating.
  • Another method of immobilization involves chemical crosslinking of inert carriers into which soluble bone matrix derived protein has been incorporated. Both techniques are effective to trap the soluble bone protein and to provide for its controlled release when implanted in vivo.
  • a preferred procedure involving demineralized, defatted, 4M guanidinium chloride extracted bone, which is typically 90% Type I collagen comprises soaking the bone in a solution of the soluble bone protein, crying the bone, and then cross-linking it with agents such as gluteraldehyde, formaldehyde, carbodiimide or the like. The cross-linking procedure effected by these agents results in a molecular collapse of the collagenous matrix structure thereby trapping incorporated soluble bone protein. Such physical entrapment within this insolubilized matrix increases the time normally required for matrix hydration by interstitial fluid so that protein release is sufficiently prolonged to allow for adequate host tissue ingrowth.
  • the surface coating is dried on the prosthesis so as to form an adherent insolubilized coating capable of releasing the protein in a time dependent manner.
  • the controlled release agent is at least one member selected from the group consisting of gelatin and fibrin, with gelatin being preferred.
  • the gelatin-bone protein coating which can be applied to a variety of prosthetic devices to initiate cartilage and bone formation at the tissue-implant interface, is insolubilized directly upon the implant by simple dehydration. The relatively insoluble nature of the dehydrated complex prolongs protein release for the appropriate period. Fixation of steel, ceramic and other metal alloy implant devices used for reconstruction or stabilization of damaged bone will be .enhanced through the stimulation of a natural osseous bridge anchoring the implant within the surrounding skeletal tissue.
  • An intended use for the method of the present invention involves the direct implantation into fracture sites or periodontal defects of treated bone into which soluble bone protein has been incorporated.
  • Bovine cancellous bone chips were demineralized in 0.6M HCl for 4 days at 4°C. Following a cold (4°C) water wash, the bone pieces were defatted in chloroformmethanol (1:1) at room temperature and allowed to air dry overnight. A 4M guanidinium chloride extraction (3 days at 4°C) removed soluble components possessing inter fering biological or immunological properties. The bone pieces were then lyophilized.
  • Small square shaped pieces (4-5 mm Long x 1-2 mm wide) of the demineralized, defatted bone were incubated under vacuum in an aqueous solution containing 800-1000 ugs Lowry protein/ml of soluble bone protein identified as Protein A VI . prepared in accordance with the process disclosed in Ser. No. 591,505.
  • One such treated bone piece absorbed approximately 200ul of solution, thereby incorporating about 200ug of soluble bone protein. Because the treated bone piece had a highly porous structure, the surface area could not be accurately determined, but was estimated to be 2-3cm 2 , which gave a coating concentration of roughly 60-100ug/cm 2 .
  • the bone pieces were lyophilized. Some of them were further treated by cross-linking with gluteraldehyde (2.5% in water) at 4°C overnight. Excess gluteraldehyde was removed with a cold water rinse.
  • Protein A VI 800ug/ml of Protein A VI . These were air dried overnight so as to coat the external surfaces of the carrier with a thin layer of semi-solid gelatin-bone protein mixture. A 10% gelatin solution solidifies at 25°C and progressively dehydrates with time forming first a viscousglue and finally a dry adherent paste.
  • Soluble bone protein identified as Protein A VI was prepared in accordance with the procedure disclosed in Ser. No. 591,505. 800 to 100ug Protein A VI was added to 1 ml of 0.1M phosphate buffer (ph 7.4) containing 50 mg fibrinogen. To this mixture was added 20 units of thrombin (20 ul of a 1000 units/ml stock solution). Within several minutes a clot formed, trapping Protein A VI inside the clot. The clot was implanted into a defect in the illiac crest of adult Fischer rats. This defect was created by removing a standarized section (0.5 cm) of crest bone form the illium using a pair of roungers.
  • Example 3 Demineralized bone cnips prepared as described in Example 1, (4 to 5mm long; 1 to 2mm wide) were incubated in a 10% gelatin solution containing 800ug/ml of the Protein A VI .
  • the treated bone chips were air dried and implanted at an ectopic intra muscular site in five to eight week old CBA male mice. Fourteen days after implantation, sites were examined by X-ray and histology. Sites implanted with gelatin-soluble bone protein coated chips showed induction of cartilage and bone. Sites implanted with gelatin-albumen coated chips showed no induction.
  • Example 4 Demineralized bone chips prepared as described in Example 1 were incubated under vacuum in an aqueous solution containing 800-1000ug/ml of Protein A VI .
  • the chips were cross-linked by soaking overnight in a 2.5% solution of gluteraldehyde at 4°C.
  • the chips were implanted into ectopic intra-muscular sites as in Example 3. Fourteen days after implantation, the sites were examined by X-ray and histology. Sites implanted with cross-linked bone protein chips showed induction of cartilage and bone formation. Sites implanted with cross-linked albumen chips showed no induction.
  • Human bone chips demineralized and defatted as described in Example 1 were incubated under vacuum in an aqueous solution containing 800-1000ug/ml of Protein A VI .
  • the chips were cross-linked with gluteraldehyde as in Example 4 were implanted in an ectopic sub-cutaneous site in white leghorn chick hatchlings. Fifteen days after implantation the sites were examined histologically. Sites implanted with cross-linked bone protein chips showed cartilage and bone deposits. Sites implanted with cross-linked albumen chips showed fibrous encapsulation only.

Abstract

A method for treating implants such as biodegradable masses, xenogenic bony implants, allografts and prosthetic devices with soluble bone protein to enhance or stimulate new cartilage and/or bone formation. Substrate immobilization or surface coating techniques retard diffusion of the soluble bone protein away from the implant site so that cartilage and bone growth is initiated.

Description

Process of Adapting Soluble Bone Protein for Use in
Stimulating Osteoinduction
Technical Field
This invention relates generally to a method for stimulating osteoinduction and more specifically to a process for adapting soluble 'regenerating' factors to effectively initiate new cartilage and/or bone growth at selected skeletal locations in humans and animals. Background Art
Regeneration of skeletal tissues is regulated by specific protein factors that are naturally present within bone matrix. During the healing process, these components stimulate certain cell populations to form new cartilage and bone tissue which serve to replace that which was lost or damaged. Such protein substances, if extracted and purified, have potential use in clinical situations where skeletal tissue regeneration is necessary to restore normal function, for example, at fracture sites and at sites of periodontal defects. In addition, such a protein substance can enhance or promote bony ingrowth into various prosthetic devices and bony implants, such as allografts, processed xenogenil bone chips and the like.
Bone matrix protein is readily soluble in body fluids. Its solubility precludes direct in_ vivo implantation at the site of a skeletal defect. For example, if a dissolvable capsule containing soluble bone protein is implanted at an ectopic intra-muscular site, no cartilage or bone induction occurs. Similarly no cartilage or bone, induction occurs when soluble bone protein is incorporated, by lyophilization, into an inert carrier (i.e., derrtineralized guanidinium chloride extracted cancellous or cortical bone chips) and implanted at ectopic sites. Diffusion of such soluble proteins away from the implant site occurs before the 1-2 days necessary for appropriate cell populations to accumulate. Thus, special procedures are required to 'immobilize' this substance in such a way that factor release coincides with the presence of sufficient numbers of responsive cell types which then will be stimulated to form cartilage and bone. Disclosure of the Invention
This application is related to copending application Ser. No. 591,505, under the title of Bone Purification Process, which discloses a process of obtaining a soluble bone matrix derived protein capable of causing undifferentiated cells to undergo chondrogenesis and to copending application Ser. No. 591,440, under the title of Process of and Material for Stimulating Growth of Cartilage and Bony Tissue at Anatomical Sites, which discloses a process in which live cells are exposed in vitro to the bone protein and then transferred in_ vivo to cause chondro/osteogenesis. The disclosures of both copending applications are incorporated by reference.
The invention provides a method of adapting soluble bone protein for use in osteoinduction and involves combining soluble bone protein purified to a state effective to initiate chondrogenesis with carrier means for retarding diffusion of said protein from a site of in vivo implantation.
In one embodiment of the invention, the carrier means for retarding diffusion of soluble bone protein comprises a biocompatible, biodegradable mass capable of releasing the protein in a time dependent manner. A preferred carrier of this class is a fibrin clot. A fibrin clot is useful in that it can be molded to fit the contours of small defects such as periodontal pockets. In another embodiment the carrier means comprises bony implant means such as allografts, specially processed xenogenic bone chips and the like, treated so as to be capable of releasing the protein in a time dependent manner. The bony implant means can be treated by soaking in a surface coating solution, such as a gelatin or fibrin solution or the like, that is capable of being dried to form an adherent, biodegradable coating. Another method of immobilization involves chemical crosslinking of inert carriers into which soluble bone matrix derived protein has been incorporated. Both techniques are effective to trap the soluble bone protein and to provide for its controlled release when implanted in vivo. A preferred procedure involving demineralized, defatted, 4M guanidinium chloride extracted bone, which is typically 90% Type I collagen, comprises soaking the bone in a solution of the soluble bone protein, crying the bone, and then cross-linking it with agents such as gluteraldehyde, formaldehyde, carbodiimide or the like. The cross-linking procedure effected by these agents results in a molecular collapse of the collagenous matrix structure thereby trapping incorporated soluble bone protein. Such physical entrapment within this insolubilized matrix increases the time normally required for matrix hydration by interstitial fluid so that protein release is sufficiently prolonged to allow for adequate host tissue ingrowth.
Another embodiment of the invention which is particularly applicable to prosthetic devices comprises the steps of soaking the prosthesis in a surface coating solution containing soluble bone protein purified to a state effective to initiate chondrogenesis and a controlled release agent. The surface coating is dried on the prosthesis so as to form an adherent insolubilized coating capable of releasing the protein in a time dependent manner. The controlled release agent is at least one member selected from the group consisting of gelatin and fibrin, with gelatin being preferred. The gelatin-bone protein coating, which can be applied to a variety of prosthetic devices to initiate cartilage and bone formation at the tissue-implant interface, is insolubilized directly upon the implant by simple dehydration. The relatively insoluble nature of the dehydrated complex prolongs protein release for the appropriate period. Fixation of steel, ceramic and other metal alloy implant devices used for reconstruction or stabilization of damaged bone will be .enhanced through the stimulation of a natural osseous bridge anchoring the implant within the surrounding skeletal tissue.
Other features and a fuller understanding of the invention will be had from the following detailed description of the best modes. Best Modes for Carrying Out the Invention The following examples more fully descr ibe the invention useful for regenerating skeletal tissue by enhancing bone ingrowth into bone defects, bony implants and prosthetic devices.
Example I
An intended use for the method of the present invention involves the direct implantation into fracture sites or periodontal defects of treated bone into which soluble bone protein has been incorporated. Bovine cancellous bone chips were demineralized in 0.6M HCl for 4 days at 4°C. Following a cold (4°C) water wash, the bone pieces were defatted in chloroformmethanol (1:1) at room temperature and allowed to air dry overnight. A 4M guanidinium chloride extraction (3 days at 4°C) removed soluble components possessing inter fering biological or immunological properties. The bone pieces were then lyophilized.
Small square shaped pieces (4-5 mm Long x 1-2 mm wide) of the demineralized, defatted bone were incubated under vacuum in an aqueous solution containing 800-1000 ugs Lowry protein/ml of soluble bone protein identified as Protein AVI. prepared in accordance with the process disclosed in Ser. No. 591,505. One such treated bone piece absorbed approximately 200ul of solution, thereby incorporating about 200ug of soluble bone protein. Because the treated bone piece had a highly porous structure, the surface area could not be accurately determined, but was estimated to be 2-3cm2, which gave a coating concentration of roughly 60-100ug/cm2. The bone pieces were lyophilized. Some of them were further treated by cross-linking with gluteraldehyde (2.5% in water) at 4°C overnight. Excess gluteraldehyde was removed with a cold water rinse.
Other small pieces of the demineralized defatted bone were soaked in a 10% gelatin solution containing
800ug/ml of Protein AVI. These were air dried overnight so as to coat the external surfaces of the carrier with a thin layer of semi-solid gelatin-bone protein mixture. A 10% gelatin solution solidifies at 25°C and progressively dehydrates with time forming first a viscousglue and finally a dry adherent paste.
Example 2 Soluble bone protein identified as Protein AVI was prepared in accordance with the procedure disclosed in Ser. No. 591,505. 800 to 100ug Protein AVI was added to 1 ml of 0.1M phosphate buffer (ph 7.4) containing 50 mg fibrinogen. To this mixture was added 20 units of thrombin (20 ul of a 1000 units/ml stock solution). Within several minutes a clot formed, trapping Protein AVI inside the clot. The clot was implanted into a defect in the illiac crest of adult Fischer rats. This defect was created by removing a standarized section (0.5 cm) of crest bone form the illium using a pair of roungers. Three to four weeks after implantation, the site of the implant was assessed histologically. Defect sites implanted with fibrin clots containing soluble bone protein showed increased amounts of cartilage or bone formation compared to the amounts of cartilage or bone formed at defectsites implanted with fibrin clots containing albumen or with fibrin clots alone.
Example 3 Demineralized bone cnips prepared as described in Example 1, (4 to 5mm long; 1 to 2mm wide) were incubated in a 10% gelatin solution containing 800ug/ml of the Protein AVI. The treated bone chips were air dried and implanted at an ectopic intra muscular site in five to eight week old CBA male mice. Fourteen days after implantation, sites were examined by X-ray and histology. Sites implanted with gelatin-soluble bone protein coated chips showed induction of cartilage and bone. Sites implanted with gelatin-albumen coated chips showed no induction.
Example 4 Demineralized bone chips prepared as described in Example 1 were incubated under vacuum in an aqueous solution containing 800-1000ug/ml of Protein AVI. The chips were cross-linked by soaking overnight in a 2.5% solution of gluteraldehyde at 4°C. The chips were implanted into ectopic intra-muscular sites as in Example 3. Fourteen days after implantation, the sites were examined by X-ray and histology. Sites implanted with cross-linked bone protein chips showed induction of cartilage and bone formation. Sites implanted with cross-linked albumen chips showed no induction.
Example 5
Human bone chips demineralized and defatted as described in Example 1 were incubated under vacuum in an aqueous solution containing 800-1000ug/ml of Protein AVI. The chips were cross-linked with gluteraldehyde as in Example 4 were implanted in an ectopic sub-cutaneous site in white leghorn chick hatchlings. Fifteen days after implantation the sites were examined histologically. Sites implanted with cross-linked bone protein chips showed cartilage and bone deposits. Sites implanted with cross-linked albumen chips showed fibrous encapsulation only.
Modifications of the above invention and materialsand procedures employed therein which are obvious to persons of skill in the art are intended to be within the scope of the following claims.

Claims

Claims
1. A method of adapting soluble bone protein for use in osteoinduction comprising combining soluble bone protein purified to a state effective to initiate chondrogenesis with carrier means for retarding diffusion of said protein from a site of in vivo implantation.
2. The method of Claim 1 wherein said carrier means comprises a biocompatible, biodegradable mass capable of releasing the protein in a time dependent manner.
3. The method of Claim 2 wherein said carrier means comprises a fibrin clot.
4. The method of Claim 1 wherein said carrier means comprises bony implant means treated so as to be capable of releasing the protein in a time dependent manner.
5. The method of Claim 4 wherein said bony implant means is treated by soaking in a surface coating solution of controlled release agent and drying to form an adherent coating capable of releasing the protein in a time dependent manner.
6. The method of Claim 4 wherein said bony implant means is treated by cross-linking so that it is capable of releasing the protein in a time dependent manner.
7. The method of Claim 1 wherein said carrier means comprises a prosthesis treated so as to be capable of releasing the protein in a time dependent manner.
8. A method of adapting soluble bone protein for use in osteoinduction comprising the steps of soaking an allograft in an aqueous solution of a controlled release agent and soluble bone protein purified to a state effective to initiate chondrogenesis, and drying the allograft to form an adherent coating capable of releasing the protein in a time dependent manner.
9. A method of adapting soluble bone protein for use in osteoinduction comprising the steps of soaking demineralized, defatted bone, extracted to remove biological or immunological properties, in an aqueous solution of bone protein purified to a state effective to initiate chondrogenesis, and cross-linking the treated bone so that it is capable of releasing the protein in a time dependent manner.
10. A method of adapting soluble bone protein for use in osteoinduction comprising the steps of soaking a prosthesis in a surface coating solution of a controlled release agent and bone protein purified to a state effective to initiate chondrogenesis and drying the prosthesis to form an adherent coating capable of releasing the protein in a time dependent manner.
11. The method of Claims wherein the controlled release agent is at least one member selected from the group consisting of gelatin and fibrin.
12. The method of Claim 8 wherein the controlled release agent is at least one member selected from the group consisting of gelatin and fibrin.
13. The method of Claim 10 wherein the controlled release agent is at least one member selected from the group consisting of gelatin and fibrin.
PCT/US1985/001291 1984-07-05 1985-07-05 Process for adapting soluble bone protein for use in stimulating osteoinduction WO1986000526A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US628,168 1984-07-05
US06/628,168 US4620327A (en) 1984-07-05 1984-07-05 Process of adapting soluble bone protein for use in stimulating osteoinduction

Publications (1)

Publication Number Publication Date
WO1986000526A1 true WO1986000526A1 (en) 1986-01-30

Family

ID=24517758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1985/001291 WO1986000526A1 (en) 1984-07-05 1985-07-05 Process for adapting soluble bone protein for use in stimulating osteoinduction

Country Status (4)

Country Link
US (1) US4620327A (en)
EP (1) EP0188552A1 (en)
AU (1) AU4601485A (en)
WO (1) WO1986000526A1 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009787A2 (en) * 1988-04-08 1989-10-19 Creative Biomolecules, Inc. Osteogenic devices
WO1990010018A1 (en) * 1989-02-23 1990-09-07 Creative Biomolecules, Inc. Bone collagen matrix for implants
US4968590A (en) * 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
WO1991005802A1 (en) * 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices
US5108753A (en) * 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
EP0485530A1 (en) * 1989-09-11 1992-05-20 Oncogen Limited Partnership TGF-$g(b) PROTEIN COMPOSITIONS FOR INHIBITION OF CELL PROLIFERATION
WO1992013565A1 (en) * 1991-01-31 1992-08-20 Shaw, Robert, Francis Growth factor containing matrix for the treatment of cartilage lesions
US5162114A (en) * 1989-02-23 1992-11-10 Stryker Corporation Bone collagen matrix for xenogenic implants
EP0530804A1 (en) * 1991-09-06 1993-03-10 Shaw, Robert Francis Kits and compositions for the treatment and repair of defects or lesions in cartilage or bone
WO1993006872A1 (en) * 1991-10-11 1993-04-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
WO1993015694A1 (en) * 1992-02-14 1993-08-19 Board Of Regents, The University Of Texas System Multi-phase bioerodible implant/carrier and method of manufacturing and using same
US5250302A (en) * 1988-04-08 1993-10-05 Stryker Corporation Osteogenic devices
EP0564502A1 (en) * 1990-11-27 1993-10-13 American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
US5258494A (en) * 1988-04-08 1993-11-02 Stryker Corporation Osteogenic proteins
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5324819A (en) * 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5344654A (en) * 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
US5354557A (en) * 1988-04-08 1994-10-11 Stryker Corporation Osteogenic devices
US5645591A (en) * 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5670336A (en) * 1988-04-08 1997-09-23 Stryker Corporation Method for recombinant production of osteogenic protein
WO1998034655A1 (en) * 1997-02-07 1998-08-13 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
WO1999037337A2 (en) * 1998-01-27 1999-07-29 St. Jude Medical, Inc. Prostheses with associated growth factors
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6371988B1 (en) 1996-10-23 2002-04-16 Sdgi Holdings, Inc. Bone grafts
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6569172B2 (en) 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6586388B2 (en) 1988-04-08 2003-07-01 Stryker Corporation Method of using recombinant osteogenic protein to repair bone or cartilage defects
US6592598B2 (en) 1996-08-30 2003-07-15 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6726718B1 (en) 1999-12-13 2004-04-27 St. Jude Medical, Inc. Medical articles prepared for cell adhesion
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
AU779278B2 (en) * 1997-02-07 2005-01-13 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US6866668B2 (en) 1998-08-14 2005-03-15 Verigen Transplantation Service International (“VTSL”) AG Methods, instruments and materials for chondrocyte cell transplantation
US6919308B2 (en) 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
US7189410B1 (en) 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7276081B1 (en) 1995-10-16 2007-10-02 Warsaw Orthopedic, Inc. Bone grafts
US7371258B2 (en) 2001-10-26 2008-05-13 St. Jude Medical, Inc. Valved prosthesis with porous substrate
US8679528B2 (en) 2002-09-10 2014-03-25 American National Red Cross Hemostatic dressing
US9131929B2 (en) 2007-08-06 2015-09-15 Stb, Ltd. Methods and dressings for sealing internal injuries

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904718A (en) * 1986-03-27 1999-05-18 Biocoll Laboratories, Inc. Delayed drug delivery system
DE3626414C2 (en) * 1986-08-05 1994-11-10 Robapharm Ag A preparation for stimulating chondrocytes and osteoblasts (ossein-hydroxyapatite complex), process for its preparation and medicament containing the same
US4743259A (en) * 1986-10-29 1988-05-10 The University Of Virginia Alumni Patents Foundation Use of demineralized bone matrix in the repair of segmental defects
US5085861A (en) * 1987-03-12 1992-02-04 The Beth Israel Hospital Association Bioerodable implant composition comprising crosslinked biodegradable polyesters
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
US5306311A (en) * 1987-07-20 1994-04-26 Regen Corporation Prosthetic articular cartilage
US5735902A (en) * 1987-07-20 1998-04-07 Regen Biologics, Inc. Hand implant device
GB8724897D0 (en) * 1987-10-23 1987-11-25 Downes S Material
US5139527A (en) * 1987-12-17 1992-08-18 Immuno Aktiengesellschaft Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation
WO1991001720A1 (en) * 1989-08-07 1991-02-21 Herman Wade Schlameus Composition and method of promoting hard tissue healing
US5256418A (en) * 1990-04-06 1993-10-26 Organogenesis, Inc. Collagen constructs
US5067963A (en) * 1990-08-21 1991-11-26 Washington University Method of making live autogenous skeletal replacement parts
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2104678C (en) * 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US5563124A (en) * 1991-04-22 1996-10-08 Intermedics Orthopedics/ Denver, Inc. Osteogenic product and process
US5290763A (en) * 1991-04-22 1994-03-01 Intermedics Orthopedics/Denver, Inc. Osteoinductive protein mixtures and purification processes
EP0672117A4 (en) * 1992-08-13 1996-06-12 Univ Pennsylvania BIOACTIVE MATERIAL TEMPLATE FOR -i(IN VITRO) SYNTHESIS OF BONE TISSUE.
US6280771B1 (en) 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5518680A (en) * 1993-10-18 1996-05-21 Massachusetts Institute Of Technology Tissue regeneration matrices by solid free form fabrication techniques
US6176874B1 (en) * 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
CA2175049A1 (en) * 1993-10-28 1995-05-04 Timothy Ringeisen Improved process and device for treating and healing a bone void
US5981825A (en) * 1994-05-13 1999-11-09 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
US5707962A (en) * 1994-09-28 1998-01-13 Gensci Regeneration Sciences Inc. Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US6180606B1 (en) 1994-09-28 2001-01-30 Gensci Orthobiologics, Inc. Compositions with enhanced osteogenic potential, methods for making the same and uses thereof
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5716616A (en) * 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US6132463A (en) * 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
US6423095B1 (en) 1995-10-16 2002-07-23 Sdgi Holdings, Inc. Intervertebral spacers
US5788976A (en) * 1996-02-12 1998-08-04 Wbk, Inc. Method for effecting bone repair
EP0891421A4 (en) 1996-03-18 2001-07-25 Univ Pennsylvania Bioactive material substrate for enhanced cellular attachment and function
US8728536B2 (en) 1996-10-16 2014-05-20 Etex Corporation Chemotherapeutic composition using nanocrystalline calcium phosphate paste
ATE220564T1 (en) * 1997-08-14 2002-08-15 Sulzer Innotec Ag COMPOSITION AND DEVICE FOR REPAIRING CARTILAGE TISSUE IN VIVO CONSISTING OF NANOCAPSULES WITH OSTEOINDUCTIVE AND/OR CHONDROINDUCTIVE FACTORS
US6551355B1 (en) 1998-08-14 2003-04-22 Cambridge Scientific, Inc. Tissue transplant coated with biocompatible biodegradable polymer
US6454811B1 (en) 1998-10-12 2002-09-24 Massachusetts Institute Of Technology Composites for tissue regeneration and methods of manufacture thereof
CA2355046A1 (en) 1998-12-14 2000-06-22 Osteotech, Inc. Bone graft and guided bone regeneration method
US20030228288A1 (en) 1999-10-15 2003-12-11 Scarborough Nelson L. Volume maintaining osteoinductive/osteoconductive compositions
US6723335B1 (en) 2000-04-07 2004-04-20 Jeffrey William Moehlenbruck Methods and compositions for treating intervertebral disc degeneration
US9387094B2 (en) 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
ES2358498T3 (en) 2000-10-24 2011-05-11 Cryolife, Inc. BIOPROSTÉTICO FILLING AND METHODS, PARTICULARLY FOR THE IN SITU TRAINING OF BIOPRÓTESIS OF INTERVERTEBRAL DISCS.
CA2425935C (en) * 2000-11-07 2011-03-29 Cryolife, Inc. Expandable foam-like biomaterials and methods
US7323193B2 (en) 2001-12-14 2008-01-29 Osteotech, Inc. Method of making demineralized bone particles
US20020114795A1 (en) * 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
EP1434608B1 (en) 2001-10-12 2018-08-22 Warsaw Orthopedic, Inc. Improved bone graft
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
SE523011C2 (en) * 2002-07-25 2004-03-23 Nobel Biocare Ab Device for implants carrying growth-stimulating substance or substances and such implant
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
CA2521623C (en) 2003-04-11 2015-03-17 Etex Corporation Osteoinductive bone material
NZ544050A (en) * 2003-06-11 2009-03-31 Osteotech Inc Osteoimplants and methods for their manufacture
US8216359B2 (en) 2004-04-15 2012-07-10 Etex Corporation Delayed-setting calcium phosphate pastes
US8721722B2 (en) 2004-10-18 2014-05-13 Ebi, Llc Intervertebral implant and associated method
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
US7780676B2 (en) 2006-07-11 2010-08-24 Ebi, Llc Intervertebral implantation apparatus
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
JP2010529987A (en) * 2007-06-15 2010-09-02 ガーネット バイオセラピューティクス インコーポレイテッド Treatment of diseases and disorders using self-replicating colony-forming cells cultured and grown in vitro
ATE547130T1 (en) * 2008-04-21 2012-03-15 Ao Technology Ag BIOCOMPATIBLE IMPLANT
US9700431B2 (en) 2008-08-13 2017-07-11 Smed-Ta/Td, Llc Orthopaedic implant with porous structural member
US10842645B2 (en) 2008-08-13 2020-11-24 Smed-Ta/Td, Llc Orthopaedic implant with porous structural member
US9616205B2 (en) * 2008-08-13 2017-04-11 Smed-Ta/Td, Llc Drug delivery implants
US8475505B2 (en) * 2008-08-13 2013-07-02 Smed-Ta/Td, Llc Orthopaedic screws
US20100042213A1 (en) 2008-08-13 2010-02-18 Nebosky Paul S Drug delivery implants
US20100042226A1 (en) * 2008-08-13 2010-02-18 Nebosky Paul S Orthopaedic implant with spatially varying porosity
EP2341852B1 (en) * 2008-08-29 2018-08-15 SMed-TA/TD, LLC Orthopaedic implant
WO2010048610A2 (en) 2008-10-24 2010-04-29 Osteotech, Inc. Compositions and methods for promoting bone formation
AU2011329054B2 (en) 2010-11-15 2015-05-28 Zimmer Orthobiologics, Inc. Bone void fillers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4430760A (en) * 1981-12-18 1984-02-14 Collagen Corporation Nonstress-bearing implantable bone prosthesis
US4440750A (en) * 1982-02-12 1984-04-03 Collagen Corporation Osteogenic composition and method
US4472840A (en) * 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
US4526909A (en) * 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4472840A (en) * 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
US4430760A (en) * 1981-12-18 1984-02-14 Collagen Corporation Nonstress-bearing implantable bone prosthesis
US4440750A (en) * 1982-02-12 1984-04-03 Collagen Corporation Osteogenic composition and method
US4526909A (en) * 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863758A (en) * 1988-04-08 1999-01-26 Stryker Corporation Nucleic acids encoding osteogenic proteins
US6586388B2 (en) 1988-04-08 2003-07-01 Stryker Corporation Method of using recombinant osteogenic protein to repair bone or cartilage defects
US5324819A (en) * 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US4968590A (en) * 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
US5670336A (en) * 1988-04-08 1997-09-23 Stryker Corporation Method for recombinant production of osteogenic protein
US6919308B2 (en) 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
US5496552A (en) * 1988-04-08 1996-03-05 Stryker Corporation Osteogenic devices
US5108753A (en) * 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US7078221B2 (en) 1988-04-08 2006-07-18 Stryker Biotech Nucleic acid molecules encoding osteogenic proteins
US6261835B1 (en) 1988-04-08 2001-07-17 Stryker Corporation Nucleotide sequences encoding osteogenic proteins
US5354557A (en) * 1988-04-08 1994-10-11 Stryker Corporation Osteogenic devices
US5344654A (en) * 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
WO1989009787A3 (en) * 1988-04-08 1990-02-08 Creative Biomolecules Inc Osteogenic devices
WO1989009787A2 (en) * 1988-04-08 1989-10-19 Creative Biomolecules, Inc. Osteogenic devices
US6551995B1 (en) 1988-04-08 2003-04-22 Stryker Corporation Osteogenic devices
US5958441A (en) * 1988-04-08 1999-09-28 Stryker Biotech Corporation Devices comprising chondrogenic protein and methods of inducing endochondral bone formation therewith
US5750651A (en) * 1988-04-08 1998-05-12 Stryker Corporation Cartilage and bone-inducing proteins
US5814604A (en) * 1988-04-08 1998-09-29 Stryker Corporation Methods for inducing endochondral bone formation comprising administering CBMP-2A, CBMP-2B, and/or virants thereof
US5250302A (en) * 1988-04-08 1993-10-05 Stryker Corporation Osteogenic devices
US6297213B1 (en) 1988-04-08 2001-10-02 Stryker Corporation Osteogenic devices
US5258494A (en) * 1988-04-08 1993-11-02 Stryker Corporation Osteogenic proteins
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US7176284B2 (en) 1988-04-08 2007-02-13 Stryker Corporation Osteogenic proteins
US5840325A (en) * 1988-04-08 1998-11-24 Stryker Corporation Osteogenic devices
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5171574A (en) * 1989-02-23 1992-12-15 Stryker Corporation Bone collagen matrix for implants
US5162114A (en) * 1989-02-23 1992-11-10 Stryker Corporation Bone collagen matrix for xenogenic implants
US4975526A (en) * 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
WO1990010018A1 (en) * 1989-02-23 1990-09-07 Creative Biomolecules, Inc. Bone collagen matrix for implants
EP0485530A4 (en) * 1989-09-11 1993-04-28 Oncogen Limited Partnership Tgf--g(b) protein compositions for inhibition of cell proliferation
EP0485530A1 (en) * 1989-09-11 1992-05-20 Oncogen Limited Partnership TGF-$g(b) PROTEIN COMPOSITIONS FOR INHIBITION OF CELL PROLIFERATION
WO1991005802A1 (en) * 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices
US5645591A (en) * 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US6605117B2 (en) 1990-05-29 2003-08-12 Stryker Corporation Synthetic bone matrix
US7208179B1 (en) 1990-11-27 2007-04-24 The American National Red Cross Methods for treating disease and forming a supplemented fibrin matrix
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
EP0564502A1 (en) * 1990-11-27 1993-10-13 American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
USRE39298E1 (en) * 1990-11-27 2006-09-19 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
USRE39321E1 (en) * 1990-11-27 2006-10-03 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
USRE39192E1 (en) * 1990-11-27 2006-07-18 American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
EP1142581A3 (en) * 1990-11-27 2002-09-11 American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
EP0564502A4 (en) * 1990-11-27 1994-01-05 American National Red Cross
US7189410B1 (en) 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7229959B1 (en) 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
EP1142581A2 (en) * 1990-11-27 2001-10-10 American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
CN1056083C (en) * 1991-01-31 2000-09-06 罗伯特弗朗西斯肖 Methods and compositions for treatment and repair of defects or lesions in cartilage
US5368858A (en) * 1991-01-31 1994-11-29 Robert F. Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage
WO1992013565A1 (en) * 1991-01-31 1992-08-20 Shaw, Robert, Francis Growth factor containing matrix for the treatment of cartilage lesions
WO1993004710A2 (en) * 1991-09-06 1993-03-18 Shaw, Robert, Francis Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
WO1993004710A3 (en) * 1991-09-06 1993-04-15 Shaw Robert F Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
EP0530804A1 (en) * 1991-09-06 1993-03-10 Shaw, Robert Francis Kits and compositions for the treatment and repair of defects or lesions in cartilage or bone
WO1993006872A1 (en) * 1991-10-11 1993-04-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
AU667877B2 (en) * 1992-02-14 1996-04-18 Board Of Regents, The University Of Texas System Multi-phase bioerodible implant/carrier and method of manufacturing and using same
WO1993015694A1 (en) * 1992-02-14 1993-08-19 Board Of Regents, The University Of Texas System Multi-phase bioerodible implant/carrier and method of manufacturing and using same
US7276081B1 (en) 1995-10-16 2007-10-02 Warsaw Orthopedic, Inc. Bone grafts
US7981156B2 (en) 1995-10-16 2011-07-19 Warsaw Orthopedic, Inc. Bone grafts
US6592599B2 (en) 1996-08-30 2003-07-15 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6599300B2 (en) 1996-08-30 2003-07-29 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6569172B2 (en) 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6592598B2 (en) 1996-08-30 2003-07-15 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US7137989B2 (en) 1996-08-30 2006-11-21 Verigen Ag Method, instruments, and kit for autologous transplantation
US6599301B2 (en) 1996-08-30 2003-07-29 Verrgen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US7048750B2 (en) 1996-08-30 2006-05-23 Verigen Ag Method, instruments, and kits for autologous transplantation
US6371988B1 (en) 1996-10-23 2002-04-16 Sdgi Holdings, Inc. Bone grafts
US6281195B1 (en) 1997-02-07 2001-08-28 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
EP1350525A2 (en) * 1997-02-07 2003-10-08 Stryker Corporation Matrix-free osteogenic devices, implants and methods thereof
EP1350525A3 (en) * 1997-02-07 2003-12-10 Stryker Corporation Matrix-free osteogenic devices, implants and methods thereof
WO1998034655A1 (en) * 1997-02-07 1998-08-13 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
AU779278B2 (en) * 1997-02-07 2005-01-13 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US6426332B1 (en) * 1997-02-07 2002-07-30 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
EP2332564A1 (en) * 1997-02-07 2011-06-15 Stryker Corporation Matrix-free osteogenic devices, implants and methods thereof
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
US7722671B1 (en) 1998-01-27 2010-05-25 St. Jude Medical, Inc. Medical devices with associated growth factors
WO1999037337A2 (en) * 1998-01-27 1999-07-29 St. Jude Medical, Inc. Prostheses with associated growth factors
WO1999037337A3 (en) * 1998-01-27 1999-09-30 St Jude Medical Prostheses with associated growth factors
US6866668B2 (en) 1998-08-14 2005-03-15 Verigen Transplantation Service International (“VTSL”) AG Methods, instruments and materials for chondrocyte cell transplantation
US6726718B1 (en) 1999-12-13 2004-04-27 St. Jude Medical, Inc. Medical articles prepared for cell adhesion
US7371258B2 (en) 2001-10-26 2008-05-13 St. Jude Medical, Inc. Valved prosthesis with porous substrate
US8679528B2 (en) 2002-09-10 2014-03-25 American National Red Cross Hemostatic dressing
US9131929B2 (en) 2007-08-06 2015-09-15 Stb, Ltd. Methods and dressings for sealing internal injuries

Also Published As

Publication number Publication date
EP0188552A1 (en) 1986-07-30
AU4601485A (en) 1986-02-10
US4620327A (en) 1986-11-04

Similar Documents

Publication Publication Date Title
US4620327A (en) Process of adapting soluble bone protein for use in stimulating osteoinduction
US5162114A (en) Bone collagen matrix for xenogenic implants
CA1195051A (en) Implantable bone prosthesis
CA2041394C (en) Osteogenic composition and implant containing same
ES2225870T3 (en) OSTEOGENIC DEVICE AND ITS PREPARATION PROCEDURE.
US4654464A (en) Bone substitute material on the base of natural bones
EP0411105B1 (en) Bone collagen matrix for implants
US5139527A (en) Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation
US7132110B2 (en) Tissue repair compositions and methods for their manufacture and use
JP2002532159A (en) Bone graft and guided bone regeneration
EP0489728B1 (en) Chemical compounds
WO1985004185A1 (en) Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
GB2148122A (en) Process for stimulating induction of bone formation and stimulation of bone regeneration by artificially perforated bone matrix
US6998135B1 (en) Demineralized corticocancellous bone sheet
JPS6162466A (en) Collagen coated bone implant piece
JPH0571266B2 (en)
JP2001500132A (en) Method for producing an implant comprising a carrier material containing a medical agent
CA1333050C (en) Biologic absorbable implant material for filling and closing soft-tissue cavities and method of its preparation
JPH08276003A (en) Head tissue restorative dental material and imbedded medical appliance
WO2003070290A1 (en) Composite biomaterial containing phospholine
CN105311676A (en) Hard tissue engineering scaffold material having bioactivity and preparation method of hard tissue engineering scaffold material
WO1988001155A1 (en) Biomaterial implant with a net positively charged surface
Ripamonti et al. Bone induction in a composite allogeneic bone/alloplastic implant
CA2027259C (en) Bone collagen matrix for implants
Hancox et al. Cross-species grafts of deproteinised bone

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU BR JP

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB IT LU NL SE